EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemical Expression of IDO and PD-L1 in Distinct Compartments of Breast Cancer Tissue: Correlation with Clinicopathological Features and Outcomes

Nikolaos Syrigos, Alexandros Mougiakos, Anastasia Konstantinidou, Emmanouil Panagiotou iD, Anastasia Karachaliou, Eleni Fyta, Ioannis Vamvakaris, Evangelia Karagianni, Elias Kotteas iD, Sophocles Lanitis iD, Christos Markopoulos, Theodoros Troupis iD und 1 weitere

Cancers · 07.04.2026 · 18 (7) · 1180

DOI: 10.3390/cancers18071180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 07.04.2026. Verfasst von Nikolaos Syrigos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, 3rd Department of Internal Medicine, Sotiria Athens General Hospital, Medical School, National & Kapodistrian University of Athens, 12…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Indoleamine 2,3-dioxygenase (IDO) is an immune checkpoint that has been shown to play a key immunomodulatory role in various solid tumors, including breast cancer (BC). Although increased IDO expression has been previously observed in some BC subtypes, mainly triple-negative BC (TNBC), the clinical relevance of this protein across the entire range of BC and its exact correlations with other immune checkpoints remain to be elucidated. We herein aimed to further investigate the differential expression patterns of IDO and programmed death-ligand 1 (PD-L1) in variable BC subtypes and in distinct compartments of breast cancer tissue, and to explore their potential associations with standard patient- and tumor-related clinicopathological parameters as well as prognosis.

Methods

This was a retrospective multi-center cohort study of 150 female patients with BC. The clinicopathological parameters analyzed were retrieved from the medical records of patients while sections from archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were also obtained for the performance of immunohistochemistry. The expression of IDO and PD-L1 was evaluated separately on tumor cells (IDO/CA, PD-L1/CA), lymphocytes (IDO/L, PD-L1/L) and stromal cells (IDO/S, PD-L1/S) and the results were correlated with the remaining clinical and pathological features of patients, as well as with local recurrence, metastasis and survival.

Results

The mean age of patients was 59.5 years (SD = 13.4 years). Positive expression of IDO/CA, IDO/L and IDO/S was found in 6%, 93.3% and 90.7% of tissue samples, respectively, while 4%, 11.2% and 6.7% of tumors were positive for PD-L1/CA, PD-L1/L and PD-L1/S, respectively. A significantly higher rate of positive IDO/CA expression was observed in triple-negative BC (TNBC) patients (p = 0.037). Positive expression of IDO-CA was also significantly associated with positivity for PD-L1/L and PD-L1/S (p = 0.001 and p = 0.015, respectively). Multivariable logistic regression analysis showed independent correlations between IDO/CA and IDO/L and the presence of invasive ductal carcinoma (IDC) (OR = 1.10; p = 0.026) and N1 status (OR = 10.93; p = 0.039), respectively, IDO/S and both N1 (OR = 14.64; p = 0.018) and positive HER2 status (OR = 6.11; p = 0.019), PD-L1/L and high Ki67 (OR = 7.96; p = 0.001) as well as negative ER (OR = 0.08; 0.003) and PR status (OR = 0.09; p = 0.002), PD-L1/S and both NST (no special type) histology (OR = 4.68; p = 0.032) and negative ER status (OR = 0.21; p = 0.044). No statistically significant associations were observed between the expression patterns of the examined biomarkers and recurrence, metastasis or survival.

Conclusions

In our study, IDO expression on tumor cells was predominantly observed in TNBC and was found to correlate with PD-L1 expression in the lymphocytic and stromal compartments. Furthermore, expression of PD-L1 among lymphocytes was found to independently correlate with unfavorable clinicopathological parameters, including high proliferation rate and negative hormone receptor status.

Schlagwörter

Stichwörter der Autor:innen

breast cancerimmunohistochemistryindoleamine 2,3-dioxygenase (IDO)programmed death-ligand 1 (PD-L1)

Autor:innen und Institutionen

  • Oncology Unit, 3rd Department of Internal Medicine, Sotiria Athens General Hospital, Medical School, National & Kapodistrian University of Athens, 124 62 Athens, Greece.
  • Department of Anatomy, Medical School, National & Kapodistrian University of Athens, 124 62 Athens, Greece.
  • Department of Oncology, Iatriko Kentro Athinon Marousi, 151 25 Athens, Greece.
  • 2nd Department of Surgery, Korgiallenio Benakeio Athens General Hospital, 115 26 Athens, Greece.

ORCID-Profile: Emmanouil Panagiotou, Elias Kotteas, Sophocles Lanitis, Theodoros Troupis

Zitieren

APA

Syrigos, N., Mougiakos, A., Konstantinidou, A., Panagiotou, E., Karachaliou, A., Fyta, E., Vamvakaris, I., Karagianni, E., Kotteas, E., Lanitis, S., Markopoulos, C., Troupis, T., & Grapsa, D. (2026). Immunohistochemical Expression of IDO and PD-L1 in Distinct Compartments of Breast Cancer Tissue: Correlation with Clinicopathological Features and Outcomes. Cancers, 18(7), 1180. https://doi.org/10.3390/cancers18071180

Vancouver

Syrigos N, Mougiakos A, Konstantinidou A, Panagiotou E, Karachaliou A, Fyta E, et al. Immunohistochemical Expression of IDO and PD-L1 in Distinct Compartments of Breast Cancer Tissue: Correlation with Clinicopathological Features and Outcomes. Cancers. 2026;18(7):1180. doi:10.3390/cancers18071180

BibTeX
@article{Syrigos2026,
  author = {Syrigos, Nikolaos and Mougiakos, Alexandros and Konstantinidou, Anastasia and Panagiotou, Emmanouil and Karachaliou, Anastasia and Fyta, Eleni and Vamvakaris, Ioannis and Karagianni, Evangelia and Kotteas, Elias and Lanitis, Sophocles and Markopoulos, Christos and Troupis, Theodoros and Grapsa, Dimitra},
  title = {Immunohistochemical Expression of IDO and PD-L1 in Distinct Compartments of Breast Cancer Tissue: Correlation with Clinicopathological Features and Outcomes},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1180},
  doi = {10.3390/cancers18071180}
}
Kostenlos starten →